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Dissecting the role of Wnt signaling and its
interactions with FGF signaling during midbrain
neurogenesis
Carlene Dyer1, Eric Blanc2, Rob J Stanley3,4, and Robert D Knight1,*
1Craniofacial Development and Stem Cell Biology; King’s College London; London, UK; 2MRC Centre for Developmental Neurobiology; King’s College London; London, UK;
3Department of Cell and Developmental Biology; University College London; London, UK; 4CoMPLEX; University College London; London, UK
Keywords: axin, GSK-3, IWR-1, mesencephalon, neuron, trigeminal, Tankyrase, zebrafish, b-catenin
Abbreviations:MTN, mesencephalic trigeminal nucleus; nTPC, nucleus of the tract of the posterior commissure; Wnt, wingless
related integrated site; FGF, Fibroblast growth factor; CA-fgfr1, constitutively active fgf receptor 1; BIO, 6-bromoindirubin-30-oxime;
IWR-1, Inhibitors of Wnt Response 1; cat, b-catenin; dkk1, dickkopf Wnt signaling pathway inhibitor 1; GSK-3, glycogen synthase
kinase; A-P, anterior-posterior; GFP, green fluorescent protein; hpf, hours post fertilization; dpf, days post fertilization.
Interactions between FGF and Wnt/ bcat signaling control development of the midbrain. The nature of this
interaction and how these regulate patterning, growth and differentiation is less clear, as it has not been possible to
temporally dissect the effects of one pathway relative to the other. We have employed pharmacological and genetic
tools to probe the temporal and spatial roles of FGF and Wnt in controlling the speciﬁcation of early midbrain neurons.
We identify a b-catenin (bcat) independent role for GSK-3 in modulating FGF activity and hence neuronal patterning.
This function is complicated by an overlap with bcat-dependent regulation of FGF signaling, through the regulation of
sprouty4. Additionally we reveal how attenuation of Axin protein function can promote ﬂuctuating levels of bcat
activity that are dependent on FGF activity. This highlights the complex nature of the interactions between FGF and
Wnt/ bcat and reveals that they act at multiple levels to control each others activity in the midbrain.
Introduction
The control of neurogenesis is critical for ensuring the correct
number of neurons form at the appropriate place during develop-
ment and regeneration. Disruption to this process occurs in a
number of congenital disorders that result in cognitive
impairment.1 Signaling pathways play a critical role in control-
ling where and when neurons form, so are presumed to be
robustly regulated, to ensure that fluctuations of any one pathway
are buffered and do not perturb neurogenesis. Buffering of sig-
naling pathway activity is achieved through regulatory interac-
tions between pathways, that act to limit or promote activity, for
instance by controlling expression of ligands or the activity of
activators or repressors. The interaction between Wnt and FGF
signaling in the developing midbrain is a well-explored example
of this interplay between 2 critical pathways.2,3
FGF and Wnt Regulation of Neurogenesis
The isthmus arises at the midbrain-hindbrain boundary
and acts as an organizer for adjacent tissues.3,4 In the
midbrain, FGFs secreted from the isthmus controls the pat-
terning of the midbrain and anterior hindbrain.5-10 At later
stages, FGF activity controls the onset of neurogenic differen-
tiation across the midbrain11,12 and acts to specify dopami-
nergic and serotenergic neurons in the ventral midbrain.13-15
Changes to midbrain identify in animals showing reduced
levels of FGF signaling are presumed to reflect a key role of
FGFs in specifying regional fate in the midbrain. Specifically,
mice or zebrafish with loss of function of Fgf8 show hyoplas-
tic midbrain and anterior hindbrain.16,17
The canonical Wnt signaling pathway activates the
nuclear transcription co-factor b-catenin (bcat) and is
important for multiple aspects of neuronal development. It
is known to be important for regulating cell proliferation
through the cell cycle regulator cyclinD1 and c-myc and
perturbations to Wnt affect midbrain size.18-23 Wnt/ bcat
signaling is also a regulator of neurogenesis and induces
expression of Neurogenin1, Neurogenenin2 and Neu-
roD1.24,25 Both early specification and later differentiation
of dopaminergic neurons in the ventral midbrain are regu-
lated by Wnt/ bcat signaling.26-30
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Cross-Talk between Wnt and FGF
A well-characterized regulatory feedback loop operates to
maintain Wnt1 and Fgf8 expression at the isthmus.2 Manipula-
tions of Wnt or FGF signaling in chick embryos have revealed
that both pathways are required for activity of the other.31 How-
ever, it is unclear if there is a hierarchy of events in which one
pathway controls the others and whether they alter the biological
responses of each other. Computational modeling of the spatial
expression of Wnt and FGF signaling pathway genes in mutant
mice has suggested that FGF signaling is required for the mainte-
nance of Wnt1 expression at the isthmus, but not induction.32 A
number of studies reveal that Wnts and FGFs have multiple roles
during midbrain development and neurogenesis, independent of
their role in conferring regional patterning. In cortical neurons,
bcat acts to promote neuronal differentiation and can override
FGF signals that promote proliferation, by inducing expression
of the pro-neurogenic factor Neurogenin1.24 Neural stem cells
likewise respond differently to Wnt and FGF signaling depen-
dent on whether both signals are present. In the presence of
FGF2, bcat promotes neural stem cell proliferation; in an absence
of FGF2 bcat promotes neuronal differentiation.33 Thus an
interplay between Wnt and FGF regulates both neuronal progen-
itor proliferation, but also differentiation. The balance of these
respective roles is therefore critical for orchestrating growth of
the developing brain and ensuring that appropriate neuronal
populations form in the correct sites.
We have previously investigated how development of early
forming dorsal brain neurons are regulated by FGF and Wnt sig-
naling.34 Using a combination of pharmacological and genetic
manipulations we found that positioning and number of mesen-
cephalic trigeminal nucleus (MTN) neurons is dependent on the
level of FGF and Wnt activity. We and others have shown that
FGF signaling from the isthmus controls neuronal differentiation
in the midbrain, through regulation of Hairy-related genes her5
and him.8,35,36 A posterior retraction of her5 expression toward
the isthmus controls where and when neuronal differentiation
occurs in the midbrain.37 Using pea3 as a readout of FGF activ-
ity, we postulated this corresponds to a gradient of FGF signaling
that is retracting posteriorly in the midbrain during develop-
ment.34 We investigated the interaction of FGF and Wnt in con-
trolling this process by applying inhibitors of FGF receptors
(SU5402) and GSK-3 (BIO). This revealed that FGF signaling is
GSK-3 dependent and that the FGF receptor inhibitor sprouty4
is regulated by Wnt signaling. It is important to understand the
nature of these interactions because of their potential impact on
the spatiotemporal control of neurogenesis in the brain. We have
therefore investigated the role of Wnt/ bcat activity in controlling
development of MTN neurons in the midbrain and how the
interaction with FGF signaling affects this process.
In this work, we identify an interaction between GSK-3 and
FGF intracellular signaling pathways, independent of the Wnt/
bcat pathway. Specifically we note that attenuation of Wnt/ bcat
signaling or of Axin function do not alter positioning of MTN
neurons, in contrast to an inhibition of GSK-3 function. Further-
more, FGF responsive genes are affected differently by bcat over-
expression and manipulation of GSK-3. Intriguingly, we find
that bcat-regulated genes do not respond in a linear manner to
Axin protein levels, suggesting that feedback loops act to modu-
late the output of Wnt/ bcat during midbrain development.
Methods
Animals and embryo manipulations
All experiments were performed in accordance with UK
Home Office regulations. Embryos were grown at 28.5C as pre-
viously described.38 Lines used were AB (considered to be wild-
type), masterblind (mbl),39, Tg[elavl3:gfp],40 Tg[dusp6:
d2eGFP],41 Tg[hsp70l:dkk1b-gfp],42 Tg[hsp70:ca-fgfr1],43 Tg
[hsp70:gal4],44 Tg[dlx5a/6a:eGFP],45 Tg[UAS:HA-b-catenin],34
Tg[TOPdGFP].46
Heat shock induction was performed by moving embryos to
37C for 2 hours at 16.5 hours post fertilization (hpf). Pharma-
cological treatments were performed by applying either SU5402
(Sigma), BIO (Invitrogen) or IWR-1 (Merck) diluted in embryo
medium as previously described.34 For all experimental condi-
tions, a minimum of n D 10 embryos were used; for each indi-
vidual experiment containing multiple conditions, embryos from
the same clutch were used to minimise variation in developmen-
tal stage.
In situ hybridization and Immunohistochemistry
Gene expression was visualised by in situ hybridization and
proteins detected by immunohistochemistry as previously
described.47,48 Antibodies used were anti-HuC/D (1 : 500, Invi-
trogen), anti-Isl1 (1 : 200, DSHB), anti-acetylated tubulin
(1 : 200, Sigma), anti-GFP (1 : 500, AMS Biotechnology), anti-
HA (1 : 300, Roche). Back labeling of axons was performed by
applying DiI or DiD to muscles of fixed 5 dpf larvae using a
sharpened tungsten needle. Fluorescent images were acquired
using a Nikon C-1 Eclipse confocal microscope and processed
using Photoshop (Adobe).
Mathematical modeling
Statistical models and analyses were generated using the R
programming language (R Development Core Team, 2010) as
described previously.34 A minimum of 10 measurements were
used for each condition in each experiment. The models used
tested variables across a number of datasets and assessed batch
effects for significance.
The model of Lee et al.49,50 describing Wnt signaling and
bcat activity was converted into equivalent code for the Python
programming language. Under the assumption that degradation
of Axin (reaction 15 in the original model, described by the rate
constant k15) is primarily through its ubiquitination by Tankyr-
ase, this model was then simulated under varying values of k15
(other rates were kept as in the original model description).
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Results
FGF signaling controls positioning and number or early
forming midbrain neurons
We have previously identified MTN neurons in the anterior
midbrain by retrograde labeling of adductor mandibulae muscles
using DiI.34 In order to ascertain whether MTN neurons also
innervate other cranial muscles, we labeled lateral rectus and leva-
tor arcus palantini muscles with DiD and adductor mandibulae
muscle with DiI in 5 day post fertilization (dpf) larvae. We
found that MTN neurons were back labeled with both DiD and
DiI, but all labeled MTN neurons were restricted to the anterior
midbrain, as we have found previously (Fig. 1A). To understand
why MTN neurons arise in the anterior midbrain, we used a
transgenic line that labels developing neurons in the developing
brain. The elavl3 gene encodes the HuC protein, a marker of dif-
ferentiated neurons.40 At 24 hpf, GFP expressing (GFPC) neu-
rons in Tg[elavl3:eGFP] embryos are observed in the dorsal
brain, in the nucleus of the posterior commissure (nTPC) and in
the anterior midbrain. GFPC MTN neurons undergo differenti-
ation in an anterior-posterior manner from 22 hpf as shown by
the presence of HuC protein (Fig. 1B). Treatment with the FGF
receptor antagonist, SU5402, at stages prior to MTN differentia-
tion, leads to an increased number of MTN neurons that lie at
more posterior positions along the midbrain, relative to control
animals (Fig. 1C).34 This suggests that FGF signaling controls
where MTN neurons will form in the midbrain during develop-
ment. Isl1 is expressed by all primary neurons in the developing
zebrafish brain.51 To determine whether FGF signaling is active
in the anterior midbrain where MTN neurons will first differen-
tiate, we labeled MTN neurons by an anti-Isl1 antibody and
compared to GFP localization in a reporter line for FGF signal-
ing that expresses GFP under the control of the Dusp6 promoter
(Tg[dusp6:d2GFP]). Strikingly, there was no co-localization of
GFP and Isl1 revealing that MTN neurons differentiate in
regions devoid of FGF signaling (Fig. 1D–I). Commensurate
with this, fgfr1 is not expressed in anterior midbrain cells at this
stage, suggesting that cells are not able to respond to FGF signal-
ing (Fig. 1J). We wished to know whether a temporal inhibition
of FGF signaling during stages prior to MTN formation would
affect the development of later-forming neuronal populations in
the midbrain including the optic tectum. To investigate this,
embryos were treated from 14–24 hpf with SU5402 or DMSO,
then drug washed away and embryos allowed to develop until
30 hpf. In SU5402 treated embryos we observed more posteri-
orly located MTN neurons in the midbrain and a smaller optic
tectum (Fig. 1K and L). Thus, a temporal inhibition of FGF sig-
naling at stages when primary neurons form, leads to perturba-
tions of midbrain neuronal architecture.
Wnt/ bcat signaling interacts with FGF to direct MTN
formation
The well documented interaction between FGF and Wnt/
bcat signaling suggests that manipulations of bcat activity would
also affect positioning of MTN neurons. We therefore compared
how alterations of Wnt relative to FGF signaling affected the
positioning of MTN neurons. MTN neuron positioning relative
to the isthmus was quantified in 24 hpf embryos under the fol-
lowing conditions: 1) expression of a constitutively active FGF
receptor (CA-Fgfr1), 2) application of SU5402, 3) expression of
the Wnt antagonist dickkopf1b (dkk1), 4) application with BIO.
All manipulations were performed between 14–24 hpf (SU5402,
BIO) or 16.5–24 hpf (CA-Fgfr1, dkk1) as we have previously
shown that MTN, but not adjacent diencephalic neurons, are
sensitive to manipulations of FGF and Wnt signaling at this
stage.34 The position of the most posteriorly located MTN neu-
rons in the midbrain was measured relative to the isthmus for
each condition and expressed as a ratio relative to the midbrain
size to compensate for any differences in size. This revealed that
over-activation of FGF resulted in an anterior shift of MTN neu-
rons (Fig. 2A). In contrast, SU5402 treated embryos displayed
posteriorly located MTN neurons relative to controls (Fig. 2B).
BIO treatment caused a similar phenotype to SU5402 treatment,
with MTN neurons present at more posterior positions in the
midbrain (Fig. 2C). In contrast, abrogation of Wnt signaling by
overexpression of dkk1 had no effect on MTN positioning
(Fig. 2D). This suggests that the posterior displacement of MTN
neurons observed in BIO treated embryos may reflect a role for
GSK-3 in controlling neuronal differentiation along the dorsal
midbrain, independent of its role in regulating Wnt signaling.
GSK3 and bcat differentially regulate FGF signaling in the
midbrain
The different changes to neuronal pattering caused by altering
Wnt and FGF activity suggests that they do not interact in a sim-
ple feedback loop to control neurogenesis in the midbrain. To
understand the importance of GSK-3 in mediating interactions
between Wnt and FGF, we compared the responses of FGF sig-
naling genes to alterations of GSK-3 and bcat activity. Previously,
we showed that BIO treatment up-regulates fgf8a expression at
the isthmus. To determine whether FGF-dependent genes such
as fgf8a are regulated by GSK-3 or bcat activity, the affects of
GSK-3 inhibition or bcat over-expression were compared when
FGF signaling was attenuated using the inhibitor SU5402.
Embryos were treated with 10mM SU5402 from 14 hpf in the
presence of varying doses of BIO or a stabilised HA tagged bcat.
Expression of fgf8a at the isthmus was assessed at 24 hpf by in
situ hybridization and found to be down-regulated by SU5402
treatment (Fig. 3A and B). In contrast, BIO causes elevated fgf8a
expression compared to controls (Fig. 3C). Surprisingly, in the
presence of both BIO and SU5402 fgf8a expression was higher
than in embryos treated with BIO alone (Fig. 3D). Overexpres-
sion of bcat resulted in reduced fgf8a expression, unlike BIO
treatment (Fig. 3E and F). In the presence of SU5402, over-
expression of bcat then rescued fgf8a relative to embryos treated
with SU5402 alone (Fig. 3G and H). These results were consis-
tent between embryos (see also Fig. S1) and reveal that fgf8a
responds differently to BIO treatment and bcat overexpression.
However, both BIO and bcat over-expression are able to rescue
fgf8a expression in the presence of SU5402.
To show how fgf8a responses compare to a transcriptional
read-out of FGF activity we assessed the response of the ETS
www.tandfonline.com e1057313-3Neurogenesis
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Figure 1. For ﬁgure legend, see page 5.
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family gene pea3 at the isthmus and midbrain signaling under
different levels of FGF, GSK-3 and bcat activity. Both SU5402
and BIO treatment cause a reduction of pea3 expression
(Fig. 3I–K). SU5402 was used at 6mM in combination with
BIO as higher SU5402 concentrations (10mM) lead to a loss of
pea3 expression, precluding quantification. In the presence of
SU5402, BIO caused a further reduction of pea3 expression than
when treated with BIO or SU5402 alone (Fig. 3L).
Overexpression of bcat also leads to a reduction of pea3
expression, similar to BIO (Fig. 3M and N). In contrast to BIO,
over-expression of bcat in the presence of SU5402 does not fur-
ther repress pea3 (Fig. 3O and P, see also Fig. S2). These differ-
ential responses of genes in the FGF signaling pathway to BIO
and bcat overexpression suggests that GSK-3 affects FGF signal-
ing in a bcat-independent manner (Table 1).
Wnt responsive genes are affected differently by changes to
b-catenin and GSK-3 activity
GSK-3 may also regulate Wnt signaling independently of its
role in inhibiting b-catenin activity in the bcat destruction com-
plex (bcatDC). To test this we investigated how genes in the
Wnt pathway are affected by inhibiting FGF signaling in con-
junction with GSK-3 inhibition compared to bcat over-expres-
sion. Application of SU5402 or BIO leads to reduced wnt1
expression (Fig. 4A–C). Application of BIO in presence of
SU5402 causes a further inhibition of wnt1 (Fig. 4D). In con-
trast to the response of wnt1 to BIO treatment, wnt1 is up-regu-
lated by overexpression of bcat (Fig. 4E and F). Application of
SU5402 abrogates this response (Fig. 4G and H, see also Fig.
S3). This reveals a differential response of wnt1 to inhibition of
GSK-3 and elevated b-catenin activity, suggesting that GSK-3
has a bcat-independent function in controlling wnt1 expression.
To determine how GSK-3 inhibition or bcat over-expression
can affect Wnt/ bcat activity, we used lef1 as a transcriptional
readout. SU5402 treatment results in down-regulation of lef1
(Fig. 4I and J). In contrast, inhibition of GSK-3 by BIO results
in a slight up-regulation of lef1 expression (Fig. 4K). In the pres-
ence of SU5402 and BIO, lef1 expression was strongly upregu-
lated (Fig. 4L). This upregulation was much greater than in
embryos treated with BIO alone, implying that GSK-3 inhibition
causes a much stronger activation of bcat when FGF signaling is
likewise inhibited. We then evaluated how overexpression of bcat
affects lef1 expression. As predicted, bcat over-expression causes
an up-regulation of lef1 (Fig. 4M and N). In the presence of
SU5402, bcat overexpression can rescue lef1 expression (Fig. 4O
and P, see also Fig. S4).
In summary, we found that lef1 expression is reduced by
SU5402, indicating a requirement for FGF activity to promote
bcat signaling. Both BIO and bcat can rescue this reduction in
the presence of SU5402, suggesting bcat regulation of lef1 is not
dependent on FGF activity.
Inhibition of Wnt signaling does not affect MTN neuron
positioning in the midbrain
To further probe the relative roles of Wnt and FGF signaling
in controlling each others activity, we focused on the role of the
key regulator of the bcat destruction complex, Axin. We have
previously described how IWR-1 acts in an antagonistic manner
to SU5402 to control the number of MTN neurons that form.34
Inhibition of Wnt signaling (by over-expression of dkk1) does
not affect MTN positioning (Fig. 2D). We therefore tested
whether stabilization of Axin, through inhibition of Tankyrase,
would affect MTN positioning in the midbrain. Although appli-
cation of varying IWR-1 doses resulted in the formation of fewer
MTN neurons (Fig. 5A) there was no effect on the distance of
MTN neurons to the isthmus (Fig. 5B). A comparison of MTN
neuron number relative to the MTN-isthmus distance showed
no correlation when embryos were exposed to IWR-1 in the pres-
ence of SU5402 (Fig. 5C). We than asked whether changes to
the MTN-isthmus distance in embryos exposed to IWR-1 and
SU5402 could be explained by the application of either IWR-1
or SU5402. We find that there is no correlation bewteen MTN
neuron number and distance to the isthmus in embryos exposed
to both IWR-1 and SU5402 (R D 0.028, Fig. 5D). Two-way
ANOVA tests revealed that IWR-1 had no significant affect (p D
0.616) on MTN neuron positioning, but SU5402 had a strong
affect (p D 0.0012). Moreover, there is no interaction effect
expected if IWR-1 and SU5402 are acting synergistically or
antagonistically (p D 0.839). In contrast, models that describe
MTN neuron number revealed that there is both a strong IWR-1
affect (p D 1.23 £ 10¡6, Table 2) and a strong interaction effect
between IWR-1 and SU5402 (p D 0.0048, Table 2). These
models indicate that although inhibition of Tankyrase results in
fewer MTN neurons, this does not occur in conjunction with
posterior shifts of MTN neurons observed following abrogation
of FGF activity (by SU5402) or inhibition of GSK-3 (by BIO).
Loss of Wnt signaling by overexpression of dkk1 likewise causes
a decrease in the number of MTN neurons forming, but this
does not correlate with altered positioning within the midbrain
Figure 1 (See previous page). FGF signaling dictates the spatial positioning of MTN neurons in the midbrain during development. DiI (red) labeling of
masseter and and DiD (blue) labeling of levator arcus palatini and lateral rectus cranial muscles in 5 dpf larvae leads to retrograde labeling of MTN neu-
rons in the anterior midbrain (A). Lateral views of Tg[elavl3:egfp] embryos labeled with anti-GFP (green) and anti-Elavl3 (HuC/D, red) reveals the presence
of more MTN neurons (arrowheads) at posterior locations in the midbrain following treatment with 40mM SU5402 from 14–24 hpf (C) relative to DMSO
exposure (B). Bracket indicates extent of MTN neurons (represented by enlarged area in B’ and C’). Dorsal (D–F) and lateral (G–I) views of 24 hpf Tg
[dusp6:d2eGFP] embryos processed with anti-GFP (green) and anti-Isl1 (red). A zoomed dorsal view (F’) reveals that neurons of the nucleus of the tract of
the posterior commissure (nTPC, asterisk) and MTN neurons (arrowheads) develop in regions devoid of anti-GFP labeling. At 24 hpf, fgfr1 expression is
absent from the anterior midbrain (J). Lateral views of 30 hpf Tg[dlx5a/6a:eGFP] embryos labeled with anti-Elavl3 (red), anti-acetylated tubulin (blue) and
anti-GFP (green) reveals more MTN neurons (arrowheads) and a reduced optic tectum (bracket) following exposure to 40mM SU5402 (L) from 14–24 hpf
compared to DMSO treated control animals (K). Nucleus of the posterior commissure (nPC), trochlear nerve (nIV). Scale bars: 50mm (A), 100mm (B–L).
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(R D 0.48, Fig. 5E). This suggests that inhibition of Wnt signal-
ing by either dkk1 over-expression or IWR-1 application does
not perturb the positioning of MTN neurons.
The Hairy-related gene her5 controls the spatiotemporal onset
of neurogenesis in the midbrain and hence where MTN neurons
form.8,35 The expression of her5 along the A-P extent of the
dorsal midbrain is controlled by GSK-3 and FGF activity.34 To
determine whether her5 shows differential responses to IWR-1
over time, we measured the spatial expression of her5 at 16.5, 18
and 20 hpf after application of IWR-1 at 14 hpf. We found that
no significant changes to her5 expression occurred initially after
exposure to IWR-1, although by 18 hpf the her5 expression was
Figure 2.MTN A-P positioning along the dorsal midbrain is regulated by FGF and GSK-3 activity, but does not require Wnt signaling. Box plots represent-
ing the minimal distance between MTN neurons and the isthmus scaled relative to midbrain size for embryos expressing CA-fgfr1 (A), exposed to 0 or
40mM SU5402 (B), exposed with 0, 1, 2, 4mM BIO (C), or expressing dkk1b (D). Signiﬁcance was determined by t-test with Welch correction (A, B, D) or by
a Kruksal-Wallis test (C) by comparing to embryos not expressing transgenes or treated only with DMSO carrier (0mM). ND 10 for each condition.
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reduced relative to control embryos (Fig. 5F–J). However, by
24 hpf, there no longer an effect of IWR-1 treatment on her5
expression in the midbrain.
Having shown that her5 is not significantly affected by IWR-1, we
then tested if inhibition ofWnt signaling would affect the response of
her5 to FGF activity. IWR-1 and SU5402 were applied simulta-
neously at 14 hpf and the spatial expression of her5 measured along
the dorsal midbrain at 24 hpf. Plots of her5 expression revealed that
IWR-1 did not alter the response of her5 SU5402 (Fig. 5K). We
confirmed this by generating models for the response of her5 to
IWR-1 and SU5402 (Table 3). These revealed that application of
IWR-1 did not have a significant affect on her5 (pD 0.322). In con-
trast, SU5402 had a significant effect (pD 0.000282). Furthermore,
IWR-1 did not significantly alter the response of her5 to SU5402
(p D 0.0763). This reveals that bcat activity is not required for the
response of her5 to FGF activity and so does not control the A-P posi-
tion ofMTNneurons in the dorsal midbrain, unlike GSK-3.
bcat activity responses to IWR-1 are not linear relative to
dose or time of exposure
Our observation that IWR-1 application caused a transient
decrease in her5 expression led us to wonder whether it caused
repression of bcat activity in a dose-dependent and uniform man-
ner. We therefore used expression of lef1 in the midbrain as a
readout of bcat activation and compared embryos treated with
IWR-1 at varying doses (20, 30, 40mM) from 14 hpf after 2.5
(16.5 hpf), 4 (18 hpf) and 6 (20 hpf) hours of exposure. Intrigu-
ingly, we found that lef1 responses were affected more by applica-
tion of 20mM IWR-1 than either 30 or 40 mM after 2.5 hours
post application (Fig. 6A–D). At later stages this changes, until
by 12 hours post application lef1 is most strongly reduced in
embryos treated with the higher doses of 30 and 40mM
(Fig. 6E–L). Why lef1 should be more affected by a lower, rather
than higher dose of IWR-1 initially is unclear. Expression of
wnt1 at the isthmus is responsive to BIO and bcat activity
Figure 3. FGF activity in the midbrain is GSK-3 dependent, but is not regulated by b-catenin. Expression of fgf8a (A–H) and pea3 (I–P) was visualized by
in situ hybridization in 24 hpf embryos treated with DMSO (A, E, I, M), SU5402 at 10mM or 6mM (B, G, J, O), BIO at 4mM (C, K), SU5402 and BIO together
(D, L), when over-expressing bcat (F, N), when over-expressing bcat and treated with SU5402 (H, P). Isthmus (i). Scale bars: 100mm.
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(Fig. 4). We found that the lowest dose of IWR-1 tested
(10mM), resulted in the strongest downregulation of wnt1
expression (Fig. 6M–P). We then turned to an alternative
reporter of Wnt/ bcat activity, the Tg[TOPdGFP] transgenic
line, to determine if these responses of lef1 represent Wnt activ-
ity. In this transgenic line, we were unable to discriminate any
differences in bcat activity when treated at different IWR-1 doses
(Table 1, data not shown). This may reflect the relative insensi-
tivity to changes in Wnt signaling levels previously reported.52
We therefore examined other readouts of bcat activity to deter-
mine how they responded to different concentrations of IWR-1
over time.
Previously, we found that the FGF receptor inhibitor, sprouty4
(spry4) shows a dual response to FGF and Wnt/ GSK-3 activity
in the midbrain.34 Strikingly, we noted that spry4 is sensitive to
the level of bcat activity independently from FGF activity. We
therefore measured the response of spry4 to varying doses of
IWR-1 from 14 hpf, to determine how similar its response was
to that of lef1. As observed for lef1, expression of spry4 was
Table 1. Summary of gene expression changes in the midbrain at 24 hpf
due to alterations of Wnt or FGF activity from 14 hpf (SU5402, IWR-1, BIO)
or 16.5 hpf (dkk1, bummar
Signaling pathway manipulation gene expression in the midbrain
Wnt FGF treatment lef1 wnt1 pea3 her5 spry4 fgf8
" BIO " # # # " "
" bcat " " # # " #
# dkk1 # # # #
# IWR-1 # " #
" CA-fgfr1 " " " " #
# SU5402 # # # # # #
" # BIO C SU5402 " # # # " "
" # bcat C SU5402 " # # #
# # IWR-1 C SU5402 # # # # #
reduced expression relative to control
no change relative to control
elevated expression relative to control
Figure 4. wnt1 in the midbrain is GSK-3 dependent, but is not regulated by b-catenin. Expression of wnt1 (A–H) and lef1 (I–P) was visualised by in situ
hybridization in 24 hpf embryos treated with DMSO (A, E, I, M), SU5402 at 10mM (B, G, J, O), BIO at 4mM (C, K), SU5402 and BIO together (D, L), when
over-expressing bcat (F, N), when over-expressing bcat and treated with SU5402 (H, P). Isthmus (i). Scale bars: 100mm.
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Figure 5. For ﬁgure legend, see page 11.
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initially reduced most strongly when 20mM IWR-1 was applied,
compared to 30 or 40mM (Fig. 7A and B). Continued exposure
to IWR-1 revealed that 20mM had the strongest effect on spry4.
In contrast, higher doses led to an elevated spry4 expression
4 hours after application relative to DMSO treated control
embryos. After 6 hours exposure, all doses of IWR-1 caused a
reduced expression of spry4, with the lower dose showing the
strongest effect. This difference in the response of spry4 to low or
high doses of IWR-1 suggests that a compensatory feedback loop
may operate to promote spry4 expression in response to reduced
bcat activity. A good candidate for this is FGF signaling, as Wnt
and FGF signaling interact to maintain the isthmus and promote
each others activity.10,31 We therefore tested if abrogation of
FGF activity would alter the dose-dependent response of spry4 to
IWR-1, by simultaneously applying both SU5402 and IWR-1.
As before, we noted that application of 20mM IWR-1 caused a
more severe reduction of spry4 that 30mM (Fig. 7C–E). Like-
wise, we observed that 10mM SU5402 caused a reduction, but
not abrogation of spry4 expression (Fig. 7F). In the presence of
SU5402, the response of spry4 to different doses of IWR-1 is
altered and the 30mM dose causes a stronger reduction than
20mM (Fig. 7G–H). This suggests that at higher doses of IWR-
1, FGF signaling compensates for reduced bcat activity, by pro-
moting spry4 expression. It also reveals that small reductions of
bcat activity do not induce this feedback response by FGF
signaling.
A model of Axin inhibition predicts oscillating bcat
activity
We found that Wnt/ bcat responsive genes lef1 and spry4 show
a non-linear response to IWR-1 and this changes relative to the
duration of exposure. One putative explanation for the differen-
tial effects of IWR-1 dosage on Wnt-target genes may therefore
be due to feedback from FGF signaling to promote elevated bcat
signaling. IWR-1 inhibition of Tnk reduces the rate of Axin pro-
tein degradation, a key limiting step in the activation of bcat.53,54
Table 2. Results from Poisson models describing MTN neuron numbers as a
function of SU5402 at 10mM (d([SU5402],10) and IWR-1 at 20 (d,([IWR120],
20) or 30mM (dr 3IWR1],30). The baseline number of MTN neurons is repre-
sented by m and interactions represented by d. Addition of IWR-1 at 20 or
30mM results in signiﬁcant changes to MTN neuron number (p<0.001), but
SU5402 at 10mM does not (p > 0.05). Application of both SU5402 and IWR-
1 results in signiﬁcant changes to MTN neuron numbers that cannot be
explained by simply additive effects, but rather represent interaction effects
e.g. dIWR1 D 20 & SU5402 D 10.
Estimate Std. Error z value Pr(>jzj)
(Intercept) 1.9617 0.1250 15.693 < 2e-16
f(IWR1)20 ¡0.7916 0.2238 ¡3.536 0.000406
f(IWR1)30 ¡1.2197 0.2515 ¡4.850 1.23e-06
f(SU5402)10 0.1316 0.1712 0.768 0.442269
f(IWR1)20:factor(SU5402)10 0.5066 0.2832 1.789 0.073613
f(IWR1)30:factor(SU5402)10 0.8670 0.3074 2.820 0.004796
Table 3. Results from generalized linear models describing expression of
her5 (scaled relative to midbrain size) as i) a function of SU5402 at 10mM
(fSU540210) and IWR-1 at either 20 or 30mM (fIWR120, fIWR130), or ii) a
function of SU5402 at 10mM relative to IWR-1 (fIWR1). Addition of IWR-1 at
20 or 30mM does not result in signiﬁcant changes to her5 expression
(p > 0.05), but SU5402 does (p < 0.001). Addition of 30mM IWR-1 in the
presence of SU5402 has an affect on her5 expression with low signiﬁcance
(p < 0.1), but overall IWR-1 does not signiﬁcantly alter the response of her5
to SU5402 (p D 0.076). Fit of data to models R2 D 0.67
i) her5 expression as a function of IWR-1 and SU5402 concentration.
Estimate Std. Error t value Pr(>jtj)
(Intercept) 0.48836 0.02693 18.136 < 2e-16 ***
fIWR120 0.03078 0.03942 0.781 0.440123
fIWR130 0.03709 0.04113 0.902 0.373348
fSU540210 ¡0.14845 0.03808 ¡3.898 0.000418 ***
fIWR120:fSU540210 ¡0.05031 0.05697 ¡0.883 0.383250
fIWR130:fSU540210 ¡0.10557 0.05817 ¡1.815 0.078133.
ii) her5 expression as a function of IWR-1 and SU5402 presence.
Estimate Std. Error t value Pr(>jtj)
(Intercept) 0.489451 0.025566 19.145 < 2e-16***
fSU540210 ¡0.145272 0.036210 ¡4.012 0.000282***
IWR1 0.001297 0.001294 1.003 0.322598
fSU540210:IWR1 ¡0.003342 0.001833 ¡1.823 0.076349.
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Figure 6. Tankyrase inhibition does not lead to linear reductions of bcat activity over time. Lateral views of 16.5 (A–D), 18 (E–H), 20 hpf (I–L) embryos
processed by in situ hybridization to reveal expression of lef1 expression following treatment with IWR-1 at 0, 20, 30, 40 mM IWR-1 from 14 hpf. Lateral
views of 24 hpf embryos processed by in situ hybridization to reveal expression of wnt1 expression following treatment with IWR-1 at 0, 20, 30, 40 mM
IWR-1 from 14 hpf. Isthmus (i). Scale bars: 100mm.
Figure 5 (See page 9). Tankyrase activity does not affect positioning of MTN neurons or FGF directed her5 expression in the dorsal midbrain. Box plot of
the number of MTN neurons (A) or MTN-isthmus distance (scaled by midbrain size, B) in 2 separate clutches of embryos (red, blue) treated with 0, 20, 30,
40mM IWR-1 from 14–24 hpf (nD 10 for each condition). Box plot of MTN-isthmus distance (scaled) in 24 hpf embryos treated with DMSO (red) or 10mM
SU5402 (blue) in conjunction with IWR-1 (C, n D 10 for each condition). Dot plot of MTN neuron number relative to MTN-isthmus distance (scaled) for
embryos treated with IWR-1 (0, 20, 30, 40mM) and SU5402 (0, 10mM) from 14 hpf (D). A correlation test reveals no correlation between neuron number
and distance (R D 0.028, n D 10 for each condition). Dot plot of MTN-isthmus distance (scaled) relative to MTN number in 24 hpf control embryos (red)
or Tg[hsp70l:dkk1b-gfp] embryos expressing dkk1b (green) from 16.5 hpf (E). A correlation test reveals no correlation between MTN neuron number and
distance (R D 0.48, n D 10 for each condition). Lateral views of 18 hpf embryos processed by in situ hybridization to reveal expression of her5 (blue,
bracket indicates expression extent in dorsal midbrain) and pax6 (red) following treatment with IWR-1 at 0, 20, 30, 40mM IWR-1 from 14 hpf (F-I). A line
plot of the her5 expression domain in the dorsal midbrain (scaled to midbrain size) in embryos treated with IWR-1 at 0, 30, 40mM from 14 hpf at 16.5, 18,
20 hpf (J, n D 10 for each condition). Box plot of her5 expression domain in the dorsal midbrain (scaled) in 24 hpf embryos treated with IWR-1 at 0, 20,
30mM and SU5402 at 0 (red) and 10mM (blue) from 14 hpf (K, n D 10 for each condition). Isthmus (i). Scale bars: 100mm.
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We used the model of Lee et al49 to examine how changing the
rate at which Axin is ubiquinated by Tnk affects bcat activity.
We modified the model such that the Axin degradation term was
dependent on the concentration of Tnk:
k15[Axin]! k15’[Tnk][Axin]
Therefore, adding IWR-1 will reduce the contribution of Tnk to
the rate (k15) at which Axin is degraded and so decrease this rate over-
all.Aplot ofAxinprotein relative todifferent rates ofAxindegradation
reveals that at high IWR-1doses (corresponding to lowconcentrations
ofTnk), Axin protein accumulates (Fig. 8A). This correspondswith a
decrease in free bcat.Wewondered howAxin concentration (and thus
Tnk activity) was related to bcat concentration in the model and
observed a nonlinear response for the bcat, divided into 2 regions
(Fig. 8B): a flat region corresponding to very lowAxin concentrations
and an inversely linear region corresponding to higher concentrations,
describedby the (fitted) power law equation:
[bcat]D 0:078[Axin]¡ 1:003
This linear region corresponds to Axin concentrations
measured from Xenopus eggs and used for construction of the
Figure 7. spry4 shows a bivalent response to changes in Wnt and FGF signaling. Polynomials were ﬁtted against the spatial expression of spry4 in the dor-
sal midbrain (mm) at 16.5, 18, 20 hpf following treatment with IWR-1 from 14 hpf (A) and showed a good ﬁt (R2 D 0.7201, n D 10 for each condition). A
line plot of the spry4 expression domain (scaled to midbrain size) in the same embryos (B) reveals that treatment with 20mM IWR-1 had the strongest
affect (n D 10 for each condition). Lateral views of 20 hpf embryos processed by in situ hybridization to reveal spry4 (blue) and pax6 (red) expression fol-
lowing treatment from 14 hpf with DMSO (C), 20mM IWR-1 (D), 30mM IWR-1 (E), 10mM SU5402 (F), 20mM IWR-1 with 10mM SU5402 (G), or 30mM IWR-1
with 10mM SU5402 (H). Isthmus (i). Scale bars: 100mm (C–H).
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model, hence provides
the region most likely
occurring in a biological
context. An analysis of
how free bcat concentra-
tion changes relate to
induction of a Wnt/ bcat
induced phenotype or
induction of siamois or
Xnr3 in Xenopus embryos
suggested it is the fold
change of free bcat con-
centration that dictates
the response to Wnt sig-
naling.50,55 Using the
same model as above, we
investigated how the
concentration of bcat
changes relative to differ-
ent rates of Axin degra-
dation prior to and after
Wnt stimulation
(Fig. 8C). As before,
high rates of Axin degra-
dation lead to high levels
of bcat. We then used
this result to ask how the
fold change of free bcat
is affected by the Axin
degradation rate
(Fig. 8D). Intriguingly,
we note that the fold
change of bcat is pre-
dicted to be relatively
high when Axin degrada-
tion is high or medium,
but that it precipitously
drops at low rates of
Axin degradation. Our
interpretation of this
model is that IWR-1 will
reduce the levels of free bcat, by promoting elevated levels of
Axin, but also allow a greater fold change in bcat levels upon
Wnt stimulation.
GSK-3 regulation of MTN positioning is independent of
bcat activity
Our results reveal that BIO inhibits GSK-3 activity, leading to
elevated bcat activity and an increase in the number of MTN
neurons that show a more posterior location in the midbrain. In
contrast, inhibition of bcat activity, through inhibition of Tank-
yrase enzyme or overexpression of dkk1, does not result in poste-
riorly located MTN neurons, but does lead to the formation of
more neurons. As GSK-3 is important for regulating multiple
intracellular signaling pathways, it may therefore have a bcat-
independent role in controlling neurogenesis. To test if Wnt
signaling can affect MTN positioning independently of GSK-3
function, we examined whether MTN development was altered
in an axin1 mutant, masterblind (mbl). We observe elevated
axin2 expression in mbl mutants indicative of increased bcat activ-
ity, similar to that observed after BIO treatment (Fig. 9A and B).
We also note that mbl mutants have significantly more MTN
neurons than in wildtype siblings, again similar to embryos
treated with BIO (Fig. 9C). However, mbl mutants do not show
posteriorly located neurons and there is no correlation between
MTN number and positioning relative to the isthmus (Fig. 9D
and E). This reveals that the increased number of MTN neurons
caused by BIO treatment can be attributed to elevated bcat activ-
ity, but the posteriorly located MTN neurons observed in these
embryos cannot be explained by increased bcat activity in the
midbrain.
Figure 8. A model for bcat activity reveals differential responses to Tnk activity. The model of Lee et al.52 and Goen-
toro and Kirschner53 was modiﬁed such that Axin degradation (reaction 15) became linearly dependent on the con-
centration of Tankyrase [Tnk] with a new second-order kinetic constant k15’. The value of k15’ was assumed to be
equal to the value of k15 (0.167), and the basal concentration of Tankyrase was assumed to be 1 (in arbitrary units).
Steady-state values of Axin and b-catenin concentration (brackets) were obtained from the simulation of the model
under varying concentrations of Tankyrase (both above and below the basal concentration indicated by a dashed ver-
tical line) and plotted as functions of the total rate of degradation of Axin (A) and as a parametric plot (B). Next, the
model was run under different rates of Axin degradation (k150[Tnk]) until it reached a steady state (s1), then stimulated
with addition of Wnt protein at tD20000 and run until a steady-state was again reached (s2). These time courses were
plotted to conﬁrm a steady state was reached (C). For each value of k15’[Tnk] the fold change in the steady-state of
[b-catenin] was calculated (s1/s2) and plotted (D).
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Discussion
We have addressed how the interplay between Wnt and FGF
activity controls the spatiotemporal specification of neurons in
the developing midbrain. Our findings reveal that a variety of
feedback and feed-forward regulatory loops operate to control
both the level and site of activity of each pathway. This has impli-
cations for where neurons form in the brain during development,
but also how many neurons will form and thus affect progenitor
cell populations important for later-forming neurons. We find
that FGF activity controls the number and positioning of MTN
neurons, whereas Wnt signaling is primarily important for con-
trolling the number of neurons that form. Furthermore, we iden-
tify a putative role for GSK-3 in modulating FGF-target gene
activity and hence neuronal positioning, independent of bcat
function.
Previously we could show that FGF activity regulates the
number and positioning of MTN neurons in the midbrain and
that this is mediated by FGF control of her5 expression. From
these findings we predicted that alterations to FGF at early stages
would affect subsequent development of later neuronal popula-
tions in the midbrain. We now present evidence that this occurs,
as expansion of the MTN, due to reductions to FGF activity over
a defined window of time, results in a smaller optic tectum. This
reveals that a disruption to FGF activity across the midbrain
upsets the controlled temporal onset of differentiation, needed
for the appropriate spatial formation of discrete neuronal popula-
tions. Sustaining an appropriate level of FGF activity at the isth-
mus is therefore crucial for controlling where and when neurons
are specified in the forming midbrain. There is a large body of
evidence for an auto-regulatory interaction between Wnt and
FGF signaling at the isthmus during midbrain development. Per-
turbations to this interaction are expected to affect midbrain pat-
terning and development. In this study we have asked whether
the interaction between Wnt and FGF occurs by control of bcat
activity or of GSK-3. Inhibition of axin1 function, over-expres-
sion of dkk1 or over-activation of Axin function using IWR-1 all
fail to alter MTN positioning, although they do increase the
number of neurons that form. In contrast, GSK-3 inhibition pro-
motes both the formation of extra neurons and the presence of
posteriorly located neurons in the midbrain (Fig. 10A). We
interpret these results to suggest that GSK-3 regulates FGF sig-
naling across the midbrain independently of bcat. It further
reveals that bcat activity controls the number of MTN neurons
that form, independently of FGF signaling, but dependent on
GSK-3 activity (Fig. 10B). Support for this interpretation comes
from a screen to identify Wnt and FGF responsive genes in the
developing tail bud of zebrafish.56 Similar to our approach, LiCl
Figure 9. Masterblind mutants possess more MTN neurons, but do not show a posterior displacement of MTN neurons. Lateral views of 24 hpf embryos
processed by in situ hybridization to reveal elevated axin2 expression in midbrain (bracket) of masterblind mutants (mbl, B), relative to wildtype siblings
(sibs, A). Box plot of the number of MTN neurons (C) or MTN-isthmus distance (scaled by midbrain size, D) in 24 hpf mbl mutants and sibs (n D 10 for
each condition). There is a strong effect by mbl on MTN number (p D 2.8£ 10¡4) but not on MTN-isthmus distance (p D 0.064). Dot plot of MTN number
against MTN-isthmus distance (scaled) for mbl mutants and sibs (E). A line of best ﬁt reveals no correlation between MTN neuron number and distance
(R D 0.19, n D 10 for each condition). Isthmus (i). Scale bars: 100mM (A,B).
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and SU5402 were used as tools
to manipulate each pathway.
Many genes examined showed
similar responses to both GSK-3
inhibition and inhibition of
FGF receptor function. Further-
more, it was shown that inhibi-
tion of GSK-3 by LiCl led to
phosphorylation of ERK and
therefore activation of ERK sig-
naling. This was interpreted to
suggest that Wnt/ bcat signaling
was controlling FGF signaling
through MAPK/ ERK activity.
Based on our comparisons
between BIO treatment relative
to bcat overexpression, we
would argue that GSK-3 has a
bcat independent function in
controlling MAPK/ERK
activity.
We found that manipula-
tions of bcat activity altered the
number of MTN neurons that
formed in the midbrain. This
could be due to a role of Wnt
signaling in controlling cell pro-
liferation. Alternatively, it may
reflect a role of Wnts in control-
ling neurogenesis. Recent find-
ings have shown that Wnt/ bcat
signaling can regulate neurogen-
esis in the flatworm Platynereis
and regulates expression of neu-
rogenic genes Neurogenin1,
Neurogenin2 and NeuroD in
mouse.24,25,57 We have previ-
ously shown that MTN devel-
opment in the midbrain is not
regulated by neurogenin func-
tion in zebrafish suggesting that
Wnt/ bcat are not directing neu-
ronal differentiation through regulation of neurogenin genes.58
Intriguingly, the action of Wnt on neurogenesis in neural stem
cells is influenced by the level of FGF activity.33 We note that in
zebrafish, increasing bcat activity promotes the formation of
more MTN neurons. When this is performed in the context of
reduced FGF activity (by varying doses of SU5402) this effect is
enhanced. This implies that in the midbrain neuronal differentia-
tion is controlled by the action of both FGF and Wnt/ bcat sig-
naling. When this is perturbed by enhancing or reducing bcat
activity (by expressing dkk1), we observe commensurate changes
to the number of neurons that form in the midbrain. We have
previously shown that temporal application of BIO at stages
when MTN neurons start to differentiate does not alter prolifera-
tion, but does cause an increase in MTN number.34 We suggest
that this reveals a role of Wnt/ bcat signaling in controlling the
process of neuronal differentiation in the midbrain.
The targeted inhibition of Wnt/ bcat activity is important for
treatment of many diseases and syndromes that involve aberrant
Wnt signaling.59 Tankyrase enzymes have been the focus for
many such efforts, due to their important functions in degrading
and so limiting Axin protein availability. The IWR and XAV939
compounds selectively inhibit Tnk, resulting in an increase in
Axin protein and hence increased bcat degradation by the
bcatDC.11,53 Initial reports describing the effect of IWR-1 dose
on bcat activity using the SuperTopFlash assay showed that an
approximate linear response occurs relative to dose. We find that
in vivo, IWR-1 does not affect bcat activity in a linear manner.
We note that Wnt/ bcat responsive genes lef1 and spry4 show a
Figure 10. Schematic for interactions between Wnt/ bcat and FGF signaling during midbrain development (A).
Secreted Wnt proteins bind frizzled (frz) and lrp5/6 cell membrane receptors complexed with dishevelled (dvl).
This results in the inhibition of the ubiquitination (Ub) and subsequent degradation of bcat by the destruction
complex (DC, purple box), incorporating Axin, APC and GSK-3 proteins. Free bcat concentration then rises and
bcat can translocate to the nucleus to activate gene expression by binding TCF or LEF transcription factors.
Inhibition of GSK-3 by BIO results in decreased bcat protein degradation. In contrast, inhibition of Tankyrase
enzyme by IWR-1 prevents ubiquitination of Axin proteins and hence increased activity of the DC. A working
model for Wnt-FGF interactions at the isthmus and in the midbrain during stages when MTN neurons form (B).
Wnt and FGF signaling co-regulate each others activity in GSK-3 dependent and independent manners. Wnt
inhibits GSK-3 activity leading to elevated bcat activity. Spry4 expression is increased in response to bcat and
FGF activity (FgfR) and acts to inhibit FgfR receptors. GSK-3 is also required for FgfR activity and acts indepen-
dently of bcat activity (green arrow). FGF signaling across the midbrain represses neurogenesis through activa-
tion of her5; as the her5 expression retracts posteriorly Wnt signaling acts to promote neuronal differentiation.
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non-linear response to IWR-1 that changes relative to the dura-
tion of exposure. We also find that the concentration of IWR-1
alters the response over time. One intriguing observation we
made is that low doses of IWR-1 initially cause a more severe
inhibition of bcat responsive genes than a higher dose. Over
time, higher concentrations of IWR-1 result in greater inhibition
of bcat-dependent responses than lower concentrations. This
change in response of bcat-responsive genes to different doses of
IWR-1 suggests compensatory feedback loops modulate their
response.
We have found that in the midbrain, FGF activity is required
for expression of wnt1 and controls bcat activity. Likewise, bcat
is able to upregulate expression of fgf8 and FGF target gene
expression in the presence of SU5402. The interaction between
Wnt and FGF signaling to maintain expression of their respective
ligands in the isthmus is well established and occurs by a positive
feedback loop.3,4 One putative explanation for the differential
effects of IWR-1 dosage on Wnt-target genes may therefore be
due to feedback from FGF signaling to promote elevated bcat
signaling. In support of this, we note that higher doses of IWR-1
causes a rapid decrease in bcat activity and leads to increased
wnt1 expression, similar to that seen by over-activation of FGF
signaling. The varying response of bcat-dependent gene expres-
sion in relation to IWR-1 dose, suggests that FGF-dependent
feedback loop induce an oscillatory response. Such oscillatory
behavior is a prediction of models generated to explain robustness
during Wnt/ bcat signaling.50,60 Our interpretation of the results
we observe in vivo, is that high doses of IWR-1 promote an
FGF-mediated feedback mechanism leading to an upregulation
of wnt1 expression. Elevated levels of Wnt protein will promote
bcatDC disassociation, until bcat-induced Axin2 levels rise suffi-
ciently to overcome Wnt action on the bcatDC and bcat activity
is then repressed. Our modification of a model for bcat activity
indicates that when Axin degradation is low, the fold change is
relatively insensitive to small changes in the degradation rate, but
that it is far more sensitive to small changes at higher rates of deg-
radation. This is result is analogous to previous analyses of bcat
fold changes, which predicted sensitive and insensitive regions as
a consequence of modifying the bcat degradation rate.50 It would
thus be valuable to further determine how the concentration of
free bcat respond to differing concentrations of IWR-1 concen-
tration over time and how this corresponds to the relative con-
centrations of Axin1 and Axin2. Even more importantly, it will
be necessary to show how bcat-activated genes respond to Tnk
inhibitors in vivo, to understand how robustness in signaling
pathway activity impacts on the biological outputs of drugs that
aim to modulate Wnt/ bcat.
In summary, we show that components of the Wnt/ bcat
pathway controls 2 aspects of midbrain development. GSK-3
acts to modulate FGF activity at the isthmus and thus controls
the spatiotemporal differentiation of early neuronal populations,
such as the MTN, across the midbrain. This function of GSK-3
appears to be independent to its role in regulating bcat, which
acts to control the number of neurons that form. How these 2
functions of Wnt signaling are integrated is unclear. One hypoth-
esis is that GSK-3 is required for normal activation of intracellu-
lar FGF targets, such as ERK. Thus, the interplay between Wnt/
bcat and FGF signaling occurs at a number of levels and involves
a complex set of feedback loops to control their relative activity.
Perturbations to any one component will lead to compensatory
activity, inducing some degree of oscillatory response. In the
presence of small molecular inhibitors, which do not respond
dynamically to such feedback loops, oscillations will be more
pronounced until they eventually reach a new equilibrium. As
recently highlighted, this is relevant for understanding how cells
in vivo may respond to drugs that target Wnt/ bcat activity.59 It
is therefore crucial to target the most appropriate component of
this pathway for effective inhibition of bcat activity with minimal
interference to other important signaling pathways.
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